Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
In addition to treating ICI-AR, TCZ demonstrated efficacy as a secondary prophylactic agent, preventing the recurrence of symptoms and lengthening ICI treatment duration after ICI rechallenge.
Authors
- R Bartolini
- Mariam Obeid (ORCID: https://orcid.org/0000-0002-9118-943X)
- Douglas Daoudlarian
- Nuria Mederos (ORCID: https://orcid.org/0000-0002-3083-0721)
- Sarah Peters (ORCID: https://orcid.org/0000-0003-1949-3995)
- Keyvan Shabafrouz
- Victor Joo
- H. Bouchaab
- Karim Abdelhamid (ORCID: https://orcid.org/0000-0002-0627-4585)
- S. Latifyan
- G Pantaleo (ORCID: https://orcid.org/0009-0000-7192-8664)
- Nabila Ferahta
- A. Stravodimou
- J. Doms
- Lucrezia Mencarelli
- P Petit
Institutions
- Centre Hospitalier Universitaire Vaudois (CH)
- ENT and Allergy (US)
- Centre Hospitalier Universitaire de Tivoli (BE)
- Hôpital Saint-Michel (FR)
- University of Lausanne (CH)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1016/j.annonc.2024.08.2340
- Citations
- 23
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.50
Funders
- Centre Hospitalier Universitaire Vaudois